1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hubei Guangji Pharmaceutical Co., Ltd Class A

Hubei Guangji Pharmaceutical Co., Ltd Class A

SSZSE:000952
5.96
CNY
+0.01
(+0.17%)
-1.26EPS
1.88BMarket Cap
Hubei Guangji Pharmaceutical Co., Ltd Class A
SZSE:000952
(Shenzhen Stock Exchange)

Recent

price

5.96

P/E

ratio

- -

div

yld

2.41%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.61
1.48
1.31
1.68
1.61
1.85
2.37
2.65
2.79
2.39
2.06
2.28
2.27
2.08
1.82
1.79
1.86
Revenue per Share
0.05
0.02
-0.32
0.01
-0.72
0.07
0.47
0.35
0.57
0.28
0.22
0.32
0.14
-0.4
-0.84
-1.16
-1.17
Basic EPS, GAAP
-0.13
-0.39
-0.03
0.16
-0.56
-0.47
0.18
0.32
0.51
0.08
0.06
-0.06
-0.45
-2.02
-0.44
0.07
- -
Free Cash Flow per Basic Share
0.04
0.07
0.09
0.09
0.07
0.12
0.12
0.11
0.17
0.1
0.15
0.1
0.11
0.09
0.14
0.15
0.14
Dividend per Share
2.67
2.7
2.38
2.37
1.65
1.7
2.17
2.51
2.89
3.18
3.96
4.25
4.25
3.85
3.04
1.89
1.72
Book Value per Share
2.46
2.45
1.75
1.72
1.01
1.06
1.56
1.95
2.34
2.62
3.49
3.8
3.82
3.24
2.36
1.3
1.15
Tangible Book Value per Share
300
306
302
291
302
302
302
302
302
306
334
344
351
354
352
348
346
Basic Weighted Avg Shares
483
453
394
487
486
560
715
802
844
731
688
786
798
738
639
624
643
Sales/Revenue/Turnover
3.88
4.06
-20.55
-9.84
-22.76
11.38
28.26
26.19
29.81
18.67
15.55
14.75
10.8
-9.92
-31.27
-17.96
-14.75
Operating Margin (%)
53
59
62
67
68
54
73
83
83
81
90
91
98
120
165
160
- -
Depreciation Expense
14
5
-96
2
-219
21
142
105
172
87
75
110
50
-140
-295
-404
-404
Net Income, GAAP
39.49
81
- -
- -
- -
- -
6.63
12.75
16.25
16.73
20.25
14.9
20.64
- -
- -
- -
- -
Effective Tax Rate (%)
2.89
1.07
-24.25
0.5
-45.02
3.73
19.85
13.13
20.35
11.89
10.85
14.02
6.31
-19.01
-46.23
-64.83
-62.94
Profit Margin (%)
52
-40
-221
-239
-216
-128
-379
-342
-259
-187
242
169
351
219
-7
-542
-701
Working Capital
122
104
125
80
317
308
133
80
28
75
84
36
248
420
395
210
101
LT Debt
839
864
760
735
505
514
659
765
881
964
1,366
1,451
1,492
1,392
1,076
627
566
Total Equity
0.29
-0.05
- -
- -
- -
2.13
12.53
8.72
12.45
5.49
4.77
5.75
2.46
- -
- -
- -
- -
Return on Invested Capital (%)
2.32
1.07
- -
- -
- -
5.8
14.79
10
13.93
8.01
6.5
7.36
3.56
- -
- -
- -
- -
Return on Capital (%)
1.75
0.6
-12.45
0.34
-36
4.14
24.32
14.89
21.04
9.48
6.4
7.77
3.4
-9.79
-24.32
-47.07
-49.72
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,088
1,097
1,216
LT Borrowings
209
142
100
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
347
347
347
Market Capitalization
2,438
2,514
1,879

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
844
858
775
Cash, Cash Equivalents & STI
278
329
265
Accounts Receivable, Net
209
209
174
Inventories
258
213
251
Total Current Liabilities
1,386
1,391
1,476
Payables & Accruals
- -
- -
- -
ST Debt
1,088
1,097
1,216
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.85%
-12.41%
-41.75%
Free Cash Flow
53.14%
125.27%
-116.07%
Net Income, GAAP
31.4%
-47.58%
36.98%
Sales/Revenue/Turnover
1.82%
-1.51%
-2.32%
Total Cash Common Dividend
9.86%
4.83%
0.96%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180
116
166
177
639
2025
148
136
- -
195
624
2026
163
149
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.16
-0.15
-0.4
-0.84
2025
-0.1
-0.11
- -
-0.89
-1.16
2026
-0.09
-0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.04
0.06
0.01
0.14
2025
0.03
0.04
- -
0.04
0.15
2026
0.03
0.03
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hubei Guangji Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company primarily engaged in the research, development, production, and sale of pharmaceutical raw materials, fine chemicals, vitamin products, and medicinal feed additives. Its core products include riboflavin (vitamin B2) in various grades such as pharmaceutical-grade, feed-grade, and human nutrition grade, riboflavin 5-phosphate sodium, vitamin B6, beta-carotene, and pharmaceutical preparations in forms such as granules, tablets, injections, ointments, and gels. The company also manufactures bulk drugs and fine chemicals and operates a strong export business serving over 80 countries. Founded in 1969 and headquartered in Wuxue City, Hubei province, China, Guangji Pharmaceutical holds several proprietary recognitions including China's Famous Trademark and has received multiple industry awards for innovation and quality. Recent major changes include strategic funding and equity involvement in subsidiaries such as Hubei Guanghua Pharmaceutical Co., Ltd., expansion of product certifications (GMP, ISO, FAMI-QS, HACCP), and operational adjustments to strengthen credit lines and guarantee capabilities for subsidiaries in 2024-2025. The company continues to focus on technological innovation and expanding its market presence domestically and internationally, maintaining its position as one of the top global manufacturers of vitamin B2 with an annual output around 3600 metric tons. It is listed on the Shenzhen Stock Exchange under the ticker 000952.SZ.